Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 1057-1065

  Pitt, Bertram ^a   Bakris, George L ^b   Bushinsky, David A ^c   Garza, Dahlia ^d   Mayo, Martha R ^d   Stasiv, Yuri ^d   Christ Schmidt, Heidi ^e   Berman, Lance ^d   Weir, Matthew R ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d Vifor (International) Inc   (Switzerland)

^e University of Iowa   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; heart failure; hyperkalaemia; patiromer

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MAGNESIUM; PATIROMER; PLACEBO; POTASSIUM; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; CARDIOVASCULAR AGENT; MINERALOCORTICOID ANTAGONIST; POLYMER; RENIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFERENCE VALUE; SINGLE BLIND PROCEDURE; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; FEMALE; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYMERS; POTASSIUM; RECURRENCE; RENAL INSUFFICIENCY, CHRONIC; RENIN;

EID: 84945979032     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.402     Document Type: Article

References (27)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
2. Zannad F, McMurray JJ, Krum H, van Veldhuisen, DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
3. Sorensen MV, Matos JE, Praetorius HA, Leipziger J,. Colonic potassium handling. Pflugers Arch 2010; 459: 645-656.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
5. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
7. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC,. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156-1162.
8. Yildirim T, Arici M, Piskinpasa S, Aybal-Kutlugun A, Yilmaz R, Altun B, Erdem Y, Turgan C,. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren Fail 2012;1095-1099.
9. Palmer BF,. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592.
10. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC,. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658-1665.
11. ® (Sodium Polystyrene) Package Insert. Sanofi-Aventis US LLC. Bridgewater, NJ 08807. Revised December 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/011287s023lbl.pdf (21 June 2015).
12. ® (Calcium Polystyrene Sulfonate) Package Insert. Sanofi-Aventis Canada Inc. Laval, Quebec H7V 0A3. Revised December 2013. Available at: http://products.sanofi.ca/en/resonium-calcium.pdf (21 June 2015).
13. Minford EJ, Hand T, Jones MC,. Constipation and colonic perforation complicating calcium resonium therapy. Postgrad Med J 1992; 68: 302.
14. Sterns RH, Rojas M, Bernstein P, Chennupati S,. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21: 733-735.
15. Food and Drug Administration. The association with colonic necrosis led the US Food and Drug Administration to issue in 2009 a warning advising against the use of SPS mixed with sorbitol. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186845.htm (17 June 2015).
16. Pappoe LS, Winkelmayer WC,. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging 2010; 27: 87-94.
17. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372: 211-221.
18. Buysse JM, Huang IZ, Pitt B,. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012; 8: 17-28.
19. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-1593.
20. Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F,. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol 2014; 173: 380-387.
21. Lazich I, Bakris GL,. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014; 34: 333-339.
22. Pitt B, Collins AJ, Reaven N, Funk S, Bakris GL, Bushinsky DA,. Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium. Circulation 2014; 130:A13320 (abstr.).
23. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-1848.
24. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial. JAMA 2015; 314: 151-161.
25. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32: 820-828.
26. ® [Full Prescribing Information]. New York, NY: Pfizer Pharmaceuticals, Inc., 2014.
27. Pfizer Pharmaceuticals. Inspra™ [Full Prescribing Information]. New York, NY Pfizer Pharmaceuticals, Inc., 2008.